Skip to main content
Isomer
  1. Home
  2. Automated
  3. NDF A-Z listing
  4. Sirolimus
S

Sirolimus

Subsidy Information and Financing Scheme

MAF

MAF

Drug Guidance

No

Post-marketing information

Yes

Summary of Biologics

No

Active ingredient: Sirolimus

General information

Subsidy Information and Financing Scheme

[MAF] Sirolimus Tablet 0.5 mg, 1 mg, 2 mg

  1. For kidney transplant immunosuppression in patients with:

  2. Evidence of CNI-induced nephrotoxicity on allograft biopsy OR

  3. Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR

  4. History of CNI drug hypersensitivity

[MAF] Sirolimus Oral Solution 1 mg/mL

  1. For kidney transplant immunosuppression in patients with:

  2. Evidence of CNI-induced nephrotoxicity on allograft biopsy OR

  3. Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR

  4. History of CNI drug hypersensitivity

Legend

This section shows the following:

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

Legend list

Indicator

Legend

SDL

Standard Drug List

MAF

Medical Assistance Fund

SVL

Subsidised Vaccine List

MSHL

Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

Drug Guidance for Subsidy

Not Applicable

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Drug availability

Formulation

Public Healthcare Institution

Tablet 0.5 mg

  1. KK Women's and Children's Hospital

  2. National University Hospital

  3. Singapore General Hospital

Tablet 1 mg

  1. Changi General Hospital

  2. National Cancer Centre

  3. National University Hospital

  4. Singapore General Hospital

Registered Product(s) Information

Clinical and product info

Clinical info

Product Info

Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch.

The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice.

Information available here are product details as registered with the HSA. As this website is updated

monthly, please refer to HSA Infosearch for the most updated product information.

Oral

Back to top